Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration
Open Access
- 20 September 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (9), e0174502
- https://doi.org/10.1371/journal.pone.0174502
Abstract
The Dual Antiplatelet Therapy (DAPT) study demonstrated that DAPT beyond 1-year after drug-eluting stent (DES) implantation, as compared with aspirin therapy alone, significantly reduced the risk of major cardiovascular and cerebrovascular events, which was mainly driven by the large risk reduction for myocardial infarction (MI). We sought to compare the largest DAPT study with other trials evaluating DAPT durations after DES implantation. By a systematic literature search, we identified 9 trials comparing prolonged- versus short-DAPT in addition to the DAPT study. The result from the DAPT study (N = 9961) with public–private collaboration was different from the pooled result of the 9 other investigator-driven trials (N = 22174) in terms of the effect of prolonged-DAPT on MI (odds ratio [OR] 0.48 [95%CI 0.38–0.62] versus pooled OR 0.88 [95%CI 0.67–1.15]: P = 0.001 for difference), while the trends for excess risk of prolonged-DAPT relative to short-DAPT for all-cause death (OR 1.31 [95%CI 0.97–1.78] versus pooled OR 1.16 [95%CI 0.92–1.45]: P = 0.53 for difference), and bleeding (OR 1.62 [95%CI 1.21–2.17] versus pooled OR 2.08 [95%CI 1.51–2.84]: P = 0.25 for difference) were consistently seen in both the DAPT and other trials. The annual rate of MI during aspirin mono-therapy in the DAPT study was much higher than that those in the other trials (2.7% versus 0.6–1.6%). Given the difference between the DAPT study and other trials, future studies should focus on certain subgroups of patients that are more or less likely to benefit from longer duration DAPT.This publication has 18 references indexed in Scilit:
- Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting StentsThe New England Journal of Medicine, 2014
- Short Versus Long Duration of DAPT After DES Implantation: A Meta-AnalysisJournal of the American College of Cardiology, 2014
- 2014 ESC/EACTS Guidelines on myocardial revascularizationEuropean Heart Journal, 2014
- Late Adverse Events After Implantation of Sirolimus-Eluting Stent and Bare-Metal StentCirculation: Cardiovascular Interventions, 2014
- Risk of Stent Thrombosis Among Bare-Metal Stents, First-Generation Drug-Eluting Stents, and Second-Generation Drug-Eluting StentsJACC: Cardiovascular Interventions, 2013
- Convincing Evidence from Controlled and Uncontrolled Studies on the Lipid-Lowering Effect of a StatinPublished by Wiley ,2012
- 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and InterventionsJournal of the American College of Cardiology, 2011
- 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive SummaryCirculation, 2011
- Trial and Error: How to Avoid Commonly Encountered Limitations of Published Clinical TrialsJournal of the American College of Cardiology, 2010
- Measuring inconsistency in meta-analysesBMJ, 2003